NASHPUBLICATIONS 06/2024 Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH EASL International Liver Congress charlie maddox Love0
NASHPUBLICATIONS 06/2024 Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of MASH and cardiovascular health in LDL receptor knockout MASH mice EASL International Liver Congress charlie maddox Love0
NASHPUBLICATIONS 06/2024 Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week global, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis EASL International Liver Congress charlie maddox Love0
NASH 11/2023 Evaluation of FASN inhibitor & GLP-1 Combination in Preclinical Mouse Model 7th Obesity and NASH Drug Development Summit Graviton Love0
NASHPUBLICATIONS 11/2023 Artificial Intelligence Based Digital Pathology Reveals Fatty Acid Synthase (FASN) Inhibitor Alone or in Combination with Semaglutide Improves Fibrosis in Diet-Induced Obese Mice with Biopsy-Confirmed NASH and Fibrosis AASLD The Liver Meeting Graviton Love0
NASHPUBLICATIONS 11/2023 Interim Analysis of FASCINATE-2 A Phase 2b Randomized, Placebo Controlled Trial Demonstrated Denifanstat Reduces Circulating Saturated Diacylglycerols and Triacylglycerols, Markers of Lipotoxicity AASLD The Liver Meeting Graviton Love0
NASH 06/2023 Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial EASL International Liver Congress Lehi Vidigal Love0
Oncology 04/2023 Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma Clinical Cancer Research Graviton Love0
Oncology 02/2023 Combination of fatty acid synthase inhibitor with tyrosine kinase inhibitors shows synergistic efficacy in HCC preclinical models, a novel potential approach for clinical development HCC-TAG Graviton Love0
NASH 01/2023 Denifanstat (DEN), a first-in-class fatty acid synthase (FASN) inhibitor, significantly reduces plasma tripalmitin, a marker of de novo lipogenesis, in NASH patients in the FASCINATE-1 and FASCINATE-2 clinical studies NASH-TAG Graviton Love0